Cardiovascular and Metabolic Disease Portfolio
CrownBio’s CVMD portfolio is a unique continuum of translational platforms that enables our clients to take strategic go/no-go decisions as they progress their therapeutic candidates through various stages of drug development.
Our clients engage with these translational platforms to model human cardiovascular and metabolic disease pathologies and use them to predict human efficacy and safety of therapeutic candidates.
Translational Solutions Leader In:
CrownBio’s CVMD portfolio includes both rodent and non-human primate (NHP) models that can be used at various stages of preclinical research to enable critical go/no-go decisions.
Next Generation Technology Development: We actively develop the next generation of technologies to address unmet needs in CVMD research and ensure that we are always ready with a solution when our clients come to us with a problem.
A Strategic Drug Development Partner: Our broad portfolio of models and services, combined with leading scientific expertise helps our customers bridge the preclinical to clinical gap with high confidence and translationally sound scientific data.
Diabetes Research Leadership
A key challenge in diabetes research and drug development is that most animal models do not completely mimic the complex states of disease progression and associated complications, thereby limiting their translatability.
CrownBio has developed unique rodent and NHP models that replicate the human pre-diabetic state, diabetes progression, and development of diabetic complications.
These models better predict human response to drug candidates in anti- diabetes programs and enable clients to test which candidate has the highest chance of success in the clinic and informs strategic go/no-go decisions.